CA3174710A1 - Methods of treating sars-cov-2 infections - Google Patents
Methods of treating sars-cov-2 infections Download PDFInfo
- Publication number
- CA3174710A1 CA3174710A1 CA3174710A CA3174710A CA3174710A1 CA 3174710 A1 CA3174710 A1 CA 3174710A1 CA 3174710 A CA3174710 A CA 3174710A CA 3174710 A CA3174710 A CA 3174710A CA 3174710 A1 CA3174710 A1 CA 3174710A1
- Authority
- CA
- Canada
- Prior art keywords
- dantrolene
- administering
- subject
- host cell
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063008486P | 2020-04-10 | 2020-04-10 | |
| US63/008,486 | 2020-04-10 | ||
| US202063062599P | 2020-08-07 | 2020-08-07 | |
| US63/062,599 | 2020-08-07 | ||
| PCT/US2021/026302 WO2021207443A1 (en) | 2020-04-10 | 2021-04-08 | Methods of treating sars-cov-2 infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3174710A1 true CA3174710A1 (en) | 2021-10-14 |
Family
ID=75787221
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3174710A Pending CA3174710A1 (en) | 2020-04-10 | 2021-04-08 | Methods of treating sars-cov-2 infections |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12605364B2 (https=) |
| EP (1) | EP4132518B1 (https=) |
| JP (1) | JP2023521163A (https=) |
| KR (1) | KR20230002371A (https=) |
| CN (1) | CN115361947A (https=) |
| AU (1) | AU2021253866A1 (https=) |
| BR (1) | BR112022020193A2 (https=) |
| CA (1) | CA3174710A1 (https=) |
| IL (1) | IL296517A (https=) |
| MX (1) | MX2022012705A (https=) |
| WO (1) | WO2021207443A1 (https=) |
| ZA (1) | ZA202210474B (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021254415A1 (en) * | 2020-04-10 | 2022-10-20 | Eagle Pharmaceuticals, Inc. | Methods of treating Severe Acute Respiratory Syndrome |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY201417A (en) * | 2017-10-20 | 2024-02-21 | Eagle Res Labs Limited | Dantrolene prodrugs and methods of their use |
| US11123328B2 (en) | 2017-11-14 | 2021-09-21 | University Health Network | Dantrolene and analogs thereof for the chronic treatment and prevention of dyssynchronous cardiac dysfunction |
| WO2019175761A1 (en) | 2018-03-12 | 2019-09-19 | Orbicular Pharmaceutical Technologies Private Limited | Ready to use dantrolene compositions |
| US12246028B2 (en) * | 2018-11-27 | 2025-03-11 | Eagle Research Labs Limited | Use of dantrolene and dantrolene prodrugs to treat radiation exposure |
| AU2021254415A1 (en) * | 2020-04-10 | 2022-10-20 | Eagle Pharmaceuticals, Inc. | Methods of treating Severe Acute Respiratory Syndrome |
-
2021
- 2021-04-08 US US17/995,602 patent/US12605364B2/en active Active
- 2021-04-08 BR BR112022020193A patent/BR112022020193A2/pt unknown
- 2021-04-08 EP EP21723473.1A patent/EP4132518B1/en active Active
- 2021-04-08 AU AU2021253866A patent/AU2021253866A1/en active Pending
- 2021-04-08 CN CN202180027309.8A patent/CN115361947A/zh active Pending
- 2021-04-08 CA CA3174710A patent/CA3174710A1/en active Pending
- 2021-04-08 KR KR1020227034976A patent/KR20230002371A/ko active Pending
- 2021-04-08 WO PCT/US2021/026302 patent/WO2021207443A1/en not_active Ceased
- 2021-04-08 MX MX2022012705A patent/MX2022012705A/es unknown
- 2021-04-08 IL IL296517A patent/IL296517A/en unknown
- 2021-04-08 JP JP2022561997A patent/JP2023521163A/ja active Pending
-
2022
- 2022-09-21 ZA ZA2022/10474A patent/ZA202210474B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN115361947A (zh) | 2022-11-18 |
| KR20230002371A (ko) | 2023-01-05 |
| US20230144719A1 (en) | 2023-05-11 |
| ZA202210474B (en) | 2025-12-17 |
| MX2022012705A (es) | 2022-11-07 |
| WO2021207443A1 (en) | 2021-10-14 |
| AU2021253866A1 (en) | 2022-10-20 |
| JP2023521163A (ja) | 2023-05-23 |
| EP4132518A1 (en) | 2023-02-15 |
| IL296517A (en) | 2022-11-01 |
| US12605364B2 (en) | 2026-04-21 |
| EP4132518C0 (en) | 2025-08-13 |
| BR112022020193A2 (pt) | 2022-11-22 |
| EP4132518B1 (en) | 2025-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2021155777A1 (zh) | 药物组合物在预防和治疗新型冠状病毒肺炎中的应用 | |
| Mancuso et al. | Peramivir: an intravenous neuraminidase inhibitor for the treatment of 2009 H1N1 influenza | |
| US12605364B2 (en) | Methods of treating SARS-CoV-2 infections | |
| US12582633B2 (en) | Methods of treating severe acute respiratory syndrome | |
| CN106511346A (zh) | 一种可用于抑制寨卡病毒感染的小分子药物及其应用 | |
| US20230181509A1 (en) | The use of diffusion enhancing compounds for treatment of viral and bacterial induced respiratory disease | |
| WO2021188787A1 (en) | Method for treatment of coronavirus infection | |
| Khubchandani et al. | Emerging therapeutic options for COVID-19 | |
| EP4132519A1 (en) | Methods of treating coronavirus infections | |
| HK40083259B (en) | Dantrolene for use in methods of treating sars-cov-2 infections | |
| HK40083259A (en) | Dantrolene for use in methods of treating sars-cov-2 infections | |
| WO2021207446A1 (en) | Methods of treating viral infections | |
| Qasem et al. | Varicella pneumonia in immunocompetent adults: symptomatic and asymptomatic cases | |
| KR20210129579A (ko) | 사스 코로나바이러스 감염증 치료용 약학적 조성물 | |
| HK40090314A (zh) | 治疗严重急性呼吸综合征的方法 | |
| RU2794315C1 (ru) | Способ профилактики или лечения коронавирусной и других острых респираторных вирусных инфекций | |
| Novozhilova et al. | Oral health in patients with COVID-19: a literature review | |
| KR20220009314A (ko) | 사스-코로나바이러스-2 감염증 예방 또는 치료용 약학 조성물 | |
| JP2024506803A (ja) | 潜在的な呼吸器ウイルス感染個体にインターフェロンベータを投与することを含む呼吸器ウイルスに対する予防的投与方法 | |
| IT202300022647A1 (it) | Uso di elysivir per il trattamento della malattia da coronavirus 2019 (covid-19) | |
| Aoki | Peramivir | |
| TW202102224A (zh) | 使用經取代之多環吡啶酮衍生物及其前藥於患有流感及嚴重流感病況之個體中治療流感 | |
| Alfano et al. | Le Infezioni in Medicina, n. 1, 11-21, 2022 | |
| Katsumi | Laninamivir octanoate offers convenient dosing for influenza treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250313 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250313 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250324 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250404 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250404 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250430 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250512 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20260211 |